Accumulated evidence obtained from various clinical trials and animal studies suggested
that cancer vaccines need better adjuvants than those that are currently licensed, which …

With the recent development of recombinant protein and peptide immunogens, the need to
improve immunogenicity has renewed interest in adjuvants. Several new adjuvants and …

Despite recent breakthroughs in the prognosis, prevention and treatment, cancer still
remains the leading cause of death and affects millions of people worldwide. With the US …

An adjuvant is defined as a product that increases or modulates the immune response
against an antigen (Ag). Based on this general definition many authors have postulated that …

The recent FDA approval of sipuleucel-T (Provenge®), a patient-specific immunotherapy for
androgen-independent prostate cancer developed by Dendreon Corporation, has provided …

New generation vaccines, particularly those based on recombinant proteins and DNA, are
likely to be less reactogenic than traditional vaccines but are also less immunogenic …

The problem with pure recombinant or synthetic antigens used in modern day vaccines is
that they are generally far less immunogenic than older style live or killed whole organism …

Adjuvants are essential components of vaccines that have been particularly effective at
promoting protective humoral immunity to infectious diseases and preventing mortality and …

Therapeutic vaccination against cancer-associated antigens represents an attractive option
for cancer therapy in view of its potential efficacy, the possibility of long-lasting immunity …

Although the discovery and characterization of multiple tumor antigens have sparked the
development of many antigen/derived cancer vaccines, many are poorly immunogenic and …